KALA BIO, Inc. (KALA) stock
Close on Nov 13, 2026Market cap $2.68MP/E –Yield –
Kala Bio statistics
55 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 0.30
- 2.22
Share statisticsIndustry
- Shares Change (YoY)
- 2681.3%
- 10.8%
- Shares Change (QoQ)
- 4.03%
- 0.50%
- Shares Held by Institutions
- 3.17%
- 56.4%
Short sellingIndustry
- Short Interest
- 382,804
- –
- Short Interest Change
- -29.0%
- -0.80%
- Short % of Shares Outstanding
- 1.98%
- 6.30%
- Days to Cover
- 1.81
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $95.50
- –
- 52-Week Low
- $0.11
- –
- 20-Day Moving Average
- $0.17
- –
- 50-Day Moving Average
- $0.33
- –
- 200-Day Moving Average
- $5.32
- –
- Average True Range (14)
- $0.03
- –
- Price Change (1 Week)
- -11.0%
- -1.15%
- Price Change (1 Month)
- -27.8%
- -4.87%
- Price Change (3 Months)
- -84.8%
- -21.0%
- Price Change (6 Months)
- -95.3%
- -20.6%
- Price Change (YTD)
- -99.5%
- -23.6%
- Price Change (1 Year)
- -99.6%
- -22.4%
- Price Change (3 Years)
- -99.9%
- -29.5%
- Price Change (5 Years)
- -100.0%
- -77.9%
- Average Volume (10 Days)
- 261,079
- –
- Average Volume (20 Days)
- 232,007
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 0.83
- 0.70
- Relative Strength Index (14)
- 25.6
- 43.4
- Volatility (1 Year)
- 136.2%
- 80.1%
- Beta (5 Years)
- 0.34
- 1.07
Returns on capitalIndustry
- Return on Equity (ROE)
- -345.3%
- -49.9%
- Return on Assets (ROA)
- -43.2%
- -40.6%
- Return on Capital Employed (ROCE)
- -232.1%
- -37.9%
Financial positionIndustry
- Current Ratio
- 6.88
- 3.30
- Quick Ratio
- 4.70
- 2.39
EfficiencyIndustry
- Profits Per Employee
- -$1.68M
- -$689.41K
- Employee Count
- 6
- 74
- WACC
- 7.60%
- 10.2%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $7.23M
- $17.76M
- Net Cash Per Share
- $0.37
- $0.80
- Equity (Book Value)
- $9.04M
- $53.89M
- Book Value Per Share
- $0.47
- $1.50
- Tangible Book Value
- $9.04M
- $27.13M
- Working Capital
- $9.04M
- $79.99M
Cash flow (TTM)Industry
Dividends and yieldsIndustry
- Earnings Yield
- -375.5%
- -21.8%
Scores and fair valueIndustry
- Altman Z-Score
- -96.83
- 0.23
- Piotroski F-Score
- 2
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | KALA | S&P 500 | Difference | KALA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.6% | -3.0% | −43.6 pts | ||
| 3 months | -85.0% | -2.8% | −82.2 pts | ||
| Year to date | -99.5% | +11.5% | −111.0 pts | ||
| 1 year | -99.6% | +13.5% | −113.0 pts | ||
| 3 years | -99.9% | +77.7% | −177.6 pts | -92.1% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -87.8% | +11.5% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
0M KALA shares were sold short on Oct 30, 2026, down 29.0% from the previous report. At recent volumes it would take 1.8 days to buy them back. Over the last 20 sessions, 39.4% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 382,804 | -29.0% | 211,044 | 1.8 |
| Oct 15, 2026 | 539,414 | -60.3% | 808,459 | 1.0 |
| Sep 30, 2026 | 1,358,824 | +205.1% | 6,221,878 | 1.0 |
| Sep 15, 2026 | 445,421 | +10.5% | 1,151,466 | 1.0 |
| Aug 31, 2026 | 403,121 | +57.9% | 286,651 | 1.4 |
| Aug 14, 2026 | 255,232 | -8.7% | 71,127 | 3.6 |
| Jul 31, 2026 | 279,430 | +8.9% | 117,662 | 2.4 |
| Jul 15, 2026 | 256,622 | +17.4% | 220,063 | 1.2 |
| Jun 30, 2026 | 218,549 | +236.8% | 213,635 | 1.0 |
| Jun 15, 2026 | 64,883 | -8.2% | 112,939 | 1.0 |
| May 29, 2026 | 70,709 | +66.0% | 69,148 | 1.0 |
| May 15, 2026 | 42,592 | -95.9% | 90,516 | 1.0 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?